US President Donald Trump has imposed a 100% tariff on imports of branded and patented pharmaceutical products beginning October 1, 2025. This decision is set to impact global pharma giants directly and could threaten billions in Indian drug exports to the United States.
According to President Trump’s directive, the new tariffs will apply unless pharmaceutical companies are actively constructing manufacturing plants within the United States—a move defined as “breaking ground” or having facilities “under construction.” The announcement, published via President Trump’s social media account, emphasizes boosting domestic manufacturing and reducing dependence on foreign pharmaceuticals.
Impact on Indian Pharma Exports
The US is the largest export market for Indian pharmaceutical manufacturers, especially in the affordable generic medicines space. In 2024, India exported USD 3.6 billion worth of pharmaceuticals to the US, a figure that rose to USD 3.7 billion in the first half of 2025 alone. Major Indian producers, including Dr. Reddy’s, Sun Pharma, Lupin, and Aurobindo, have built their businesses around the US market’s demand for cost-effective alternatives to branded drugs.
While the new policy explicitly targets branded and patented medicines—a segment predominantly controlled by multinational drug giants—uncertainty persists over whether complex generics and specialty medicines from Indian firms might also face scrutiny or expanded tariff coverage.
Escalating Trade Pressures and Existing Tariff Challenges
Trump’s move comes on top of existing tariff pressures. Many Indian pharmaceutical exports are already subject to a 50% import tariff in the US, which includes a 25% penalty tied to India’s continued import of Russian oil.
Industry experts caution that the new tariffs could destabilize export flows and raise costs for US consumers.
